Delta-like ligand 4 mediated myeloid-derived suppressor cell metabolic reprogramming promotes neoadjuvant therapy resistance in titin-inactivated triple-negative breast cancer
Open Access
- 2 December 2025
- journal article
- research article
- Published by Springer Nature in Molecular Biomedicine
- Vol. 6 (1) , 128
Abstract
Triple-negative breast cancer (TNBC) is characterized by complex genomic background and treatment resistance. We first defined “Titin (TTN) inactivation”, a state of TTN expression deficiency or mutation, affecting tumor progression. However, how TTN inactivation regulates immune escape and affects therapeutic resistance remains unclear. Using whole-exome sequencing, single-cell transcriptome sequencing, and spatial transcriptome sequencing, we screened the clinical features of TNBC patients with TTN inactivation who accepted neoadjuvant therapy. Meanwhile, we used CRISPR-Cas9 technology to construct various mutant TNBC cell lines. Lentiviral vector carrying TTN and delta-like ligand 4 (DLL4) was validated in vivo to verify potential mechanism. Myeloid-derived suppressor cells (MDSCs) metabolic function was measured using glycolysis-related molecular experiments. Immunotherapeutic agents against TNBC with TTN inactivation were explored in the orthotopic MCT4 fl/fl genetically modified mouse model. DLL4-regulated ecological niche was established in TNBC with TTN inactivation. Mechanistically, TTN deficiency and mutation led to DLL4 secretion in TNBC. DLL4 enhanced MCT4-mediated glycolysis via MDSCs-derived NOTCH2 signaling pathway, driving the malignant function and lactate acid excretion of MDSCs. DLL4-derived MDSCs promoted stemness-mediated drug resistance by inducing histone lactate modification in TNBC, suppressing the anti-tumor activities of CD8 + T cells. Blocking the DLL4-MCT4 axis stimulated anti-tumor immunity and synergized with anti-PD-1, improving response rates for first-line neoadjuvant therapy in TNBC. Our study revealed intrinsic mechanism by which TTN regulates the tumor immune microenvironment and provided a potential target for immunotherapy in TNBC with TTN inactivation.Keywords
Funding Information
- Beijing-Tianjin-Hebei Basic Research Project of Tianjin Science and Technology Bureau (22JCZXJC00040)
- Public Health Science and Technology Major Project of the Tianjin Science and Technology Bureau (21ZXGWSY00020)
This publication has 24 references indexed in Scilit:
- Serum Amyloid A1 Mediates Paclitaxel Resistance via MD2‐Dependent Pathways in Triple‐Negative Breast CancerDrug Development Research, 2025
- Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancerBiomedicine & Pharmacotherapy, 2024
- ASF1A-dependent P300-mediated histone H3 lysine 18 lactylation promotes atherosclerosis by regulating EndMTActa Pharmaceutica Sinica B, 2024
- Notch-mediated cellular interactions between vascular cellsCurrent Opinion in Cell Biology, 2023
- Complex heatmap visualizationiMeta, 2022
- The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cellsCellular Signalling, 2018
- A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsInvestigational New Drugs, 2018
- Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targetsBiochemical and Biophysical Research Communications, 2018
- Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancerCancer Medicine, 2018
- EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomasCancer Letters, 2017